Atika Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Atika Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-65,000	Closed	-$1.68M	–	96
2021 Q1	$1.68M	Sell	65,000 -105,247	-62%	-$4.63M	0.15%	87
2020 Q4	$9.1M	Buy	+170,247	New	+$8.45M	0.71%	64
2020 Q3	–	Sell	-100,000	Closed	-$4.32M	–	107
2020 Q2	$4.85M	Buy	+100,000	New	+$4.8M	0.63%	64
2017 Q2	–	Sell	-65,200	Closed	-$2.24M	–	78
2017 Q1	$2.24M	Buy	+65,200	New	+$2.3M	1.1%	43
2015 Q2	–	Sell	-35,000	Closed	-$1.35M	–	68
2015 Q1	$1.14M	Sell	35,000 -83,500	-70%	-$2.87M	0.76%	51
2014 Q4	$3.76M	Sell	118,500 -33,500	-22%	-$950K	2.75%	10
2014 Q3	$3.77M	Sell	152,000 -43,000	-22%	-$1.01M	2.89%	7
2014 Q2	$4.41M	Buy	195,000 +15,300	+9%	+$319K	3.58%	5
2014 Q1	$4.37M	Buy	179,700 +4,725	+3%	+$120K	3.72%	7
2013 Q4	$4.37M	Buy	+174,975	New	+$4.13M	3.89%	4

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Atika Capital Management's ACAD Position: Q2 2021 in Review

Atika Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 65,000 shares — an estimated $1.68M sold.

Atika Capital Management first reported a position in ACAD in Q4 2013 and held it in 10 quarters. The position peaked at $9.1M in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Atika Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Atika Capital Management sold 65,000 Acadia Pharmaceuticals shares in Q2 2021, an estimated $1.68M.
Atika Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Atika Capital Management's Acadia Pharmaceuticals position peaked at $9.1M in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Atika Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.